Phase I/II trial of CFT1946 in mutant BRAF V600 tumors - ViDoe

Phase I/II trial of CFT1946 in mutant BRAF V600 tumors

No views

16 hours ago

Phase I/II trial of CFT1946 in mutant BRAF V600 tumors

Phase I/II trial of CFT1946 in mutant BRAF V600 tumors

$Phase I\/II trial of CFT1946 in mutant BRAF V600 tumors$

2:08

Phase I\/II trial of CFT1946 in mutant BRAF V600 tumors

Treatment selection for stage III BRAF-mutant melanoma

1:17

Treatment selection for stage III BRAF-mutant melanoma

BRAF Mutations Across Cancers

5:14

BRAF Mutations Across Cancers

by European Society for Medical Oncology (ESMO)

What is a BRAF-V600E mutation?

1:49

What is a BRAF-V600E mutation?

by American Lung Association

Treating BRAF V600E-mutant NSCLC with dabrafenib and trametinib

2:56

Treating BRAF V600E-mutant NSCLC with dabrafenib and trametinib

SECOMBIT – determining the order of sequential therapies in metastatic melanoma with BRAF mutations

1:48

SECOMBIT – determining the order of sequential therapies in metastatic melanoma with BRAF mutations

BRAF Targeted Therapy - Melanoma Education Symposium, Peter Boasberg MD

22:44

BRAF Targeted Therapy - Melanoma Education Symposium, Peter Boasberg MD

by ImmunoOncology

Triplet Regimens in BRAF-Mutant Metastatic CRC

7:02

Triplet Regimens in BRAF-Mutant Metastatic CRC

BRAF-Mutated mCRC: From Diagnosis to Treatment

1:35:47

BRAF-Mutated mCRC: From Diagnosis to Treatment

Impact of BRAF-V600E mutation on the tumour microenvironment and associated genomic alterations ...

10:08

Impact of BRAF-V600E mutation on the tumour microenvironment and associated genomic alterations ...

Advances in Therapy for BRAF-mutant Melanoma

27:28

Advances in Therapy for BRAF-mutant Melanoma

by HMP Education

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

5:19

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

Prognostic value of BRAFV600 mutations in stage 3 cutaneous melanoma patients

5:02

Prognostic value of BRAFV600 mutations in stage 3 cutaneous melanoma patients

Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhD

47:45

Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhD

by The Society for Translational Oncology

Tumor Mutational Burden in Key Phase III Trials of NSCLC

7:00

Tumor Mutational Burden in Key Phase III Trials of NSCLC

BRAF in Melanoma Explained

1:23

BRAF in Melanoma Explained

by AIMatMelanoma

BRAF mutations and MEK inhibitors

1:22

BRAF mutations and MEK inhibitors

by Target Cancer

BRAF Mutations in Colorectal Cancer

2:33

BRAF Mutations in Colorectal Cancer

BRAF: from gene to cancer therapy

3:03

BRAF: from gene to cancer therapy

Prognosticating BRAF-Mutant mCRC

2:18

Prognosticating BRAF-Mutant mCRC